New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

May 20, 1999

Primary Completion Date

April 26, 2019

Study Completion Date

April 26, 2019

Conditions
Cushing SyndromeEndocrine Disease
Interventions
DRUG

Pentetreotide

Binds primarily to the somatostatin receptors subtypes (sst) 2 and 5. A high dose (18mCi) was used if the conventional dose (6mCi) was negative and scheduling was available. High doses limited to 3 over the course of the study.

DRUG

18F-DOPA

18F-DOPA is a radiolabeled amino acid used as a radiotracer in positron emission tomography (PET). Limited to 3 doses over the course of the study.

DEVICE

CT scan

CT scan of chest, abdomen, neck and /or pelvis

DEVICE

MRI

MRI scan of head/pituitary, chest, abdomen, neck and /or pelvis

DRUG

18-FDG

FDG PET scan of body

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH